子宫托治疗女性盆腔器官脱垂并发症的研究

doi:10.12280/gjfckx.20210297

摘要/Abstract

摘要：

盆腔器官脱垂（pelvic organ prolapse,POP）是部分老年女性面临的问题,且发病率逐年升高,子宫托治疗是该疾病的一种保守治疗方法,也是一线治疗方法。但如果使用不当,治疗过程中也可能会出现多种并发症,严重者不得不需要手术干预,有的甚至会威胁生命。目前国际上关于子宫托治疗缺乏统一指南,治疗操作不规范和患者依从性差与并发症发生密切相关。总结归类运用子宫托治疗的相关并发症,介绍一种子宫托相关并发症的评级方法,针对并发症的预防提出了部分解决方法。

关键词: 子宫托, 盆腔器官脱垂, 物理治疗方法, 打印,三维, 阴道瘘, 并发症

Abstract:

Pelvic organ prolapse(POP) is a problem faced by many elderly women, and the incidence is increasing year by year. The pessary treatment is not only a conservative treatment method but also a first-line treatment method for this disease. However, if it is used improperly, multiple complications may occur during the treatment process, severe cases have to receive surgical intervention, and some may even be life-threatening. At present, there is a lack of unified guidelines for the treatment of pessaries in the world. Non-standard treatment operations and poor patient compliance are closely related to the occurrence of complications. This article focuses on summarizing and categorizing the currently reported pessary-related complications, introduces a grading method for pessary-related complications, and proposes a few ways to the prevention of complications as following.

Key words: Pessaries, Pelvic organ prolapse, Physical therapy modalities, Printing,three-dimensional, Vaginal fistula, Complications

王丽, 王佳, 魏筱萱, 牛海英. 子宫托治疗女性盆腔器官脱垂并发症的研究[J]. 国际妇产科学杂志, 2021, 48(6): 700-703.

WANG Li, WANG Jia, WEI Xiao-xuan, NIU Hai-ying. Research on the Complications of Pessary in the Treatment of Female Pelvic Organ Prolapse[J]. Journal of International Obstetrics and Gynecology, 2021, 48(6): 700-703.

参考文献 33

[1]	Chen CJ, Thompson H. Uterine Prolapse[M]. Treasure Island(FL): StatPearls Publishing, 2021.
[2]	Pang H, Zhang L, Han S, et al. A nationwide population-based survey on the prevalence and risk factors of symptomatic pelvic organ prolapse in adult women in China-a pelvic organ prolapse quantification system-based study[J]. BJOG, 2021,128(8):1313-1323. doi: 10.1111/1471-0528.16675. doi: 10.1111/1471-0528.16675
[3]	Bugge C, Adams EJ, Gopinath D, et al. Pessaries (mechanical devices) for managing pelvic organ prolapse in women[J]. Cochrane Database Syst Rev, 2020(11):CD004010. doi: 10.1002/14651858.CD004010.pub4. doi: 10.1002/14651858.CD004010.pub4
[4]	Kato J, Nagata C, Miwa K, et al. Pelvic organ prolapse and Japanese lifestyle: prevalence and risk factors in Japan[J]. Int Urogynecol J, 2021 Feb 12. doi: 10.1007/s00192-021-04672-7. doi: 10.1007/s00192-021-04672-7
[5]	Cundiff GW, Weidner AC, Visco AG, et al. A survey of pessary use by members of the American urogynecologic society[J]. Obstet Gynecol, 2000,95(6 Pt 1):931-935. doi: 10.1016/s0029-7844(00)00788-2. doi: 10.1016/s0029-7844(00)00788-2 pmid: 10831995
[6]	Harvey MA, Lemieux MC, Robert M, et al. Guideline No. 411: Vaginal Pessary Use[J]. J Obstet Gynaecol Can, 2021,43(2):255-266.e1. doi: 10.1016/j.jogc.2020.11.013. doi: 10.1016/j.jogc.2020.11.013
[7]	Giannini A, Russo E, Cano A, et al. Current management of pelvic organ prolapse in aging women: EMAS clinical guide[J]. Maturitas, 2018,110:118-123. doi: 10.1016/j.maturitas.2018.02.004. doi: S0378-5122(18)30080-X pmid: 29444759
[8]	Vardon D, Martin-Lasnel M, Agostini A, et al. Vaginal pessary for pelvic organ prolapse: A survey among french gynecological surgeons[J]. J Gynecol Obstet Hum Reprod, 2021,50(4):101833. doi: 10.1016/j.jogoh.2020.101833. doi: 10.1016/j.jogoh.2020.101833
[9]	Umachanger JK, Marcussen ML, Bøggild H, et al. First-line treatment of pelvic organ prolapse and discontinuation of pessary treatment[J]. Int Urogynecol J, 2020,31(9):1813-1819. doi: 10.1007/s00192-020-04338-w. doi: 10.1007/s00192-020-04338-w
[10]	Gabriel I, Kalousdian A, Brito LG, et al. Pelvic organ prolapse after 3 modes of hysterectomy: long-term follow-up[J]. Am J Obstet Gynecol, 2021,224(5):496.e1-496.e10. doi: 10.1016/j.ajog.2020.11.008. doi: 10.1016/j.ajog.2020.11.008 pmid: 33207236
[11]	Miceli A, Dueñas-Diez JL. Effectiveness of ring pessaries versus vaginal hysterectomy for advanced pelvic organ prolapse. A cohort study[J]. Int Urogynecol J, 2019,30(12):2161-2169. doi: 10.1007/s00192-019-03919-8. doi: 10.1007/s00192-019-03919-8
[12]	Ma C, Xu T, Kang J, et al. Factors associated with pessary fitting in women with symptomatic pelvic organ prolapse: A large prospective cohort study[J]. Neurourol Urodyn, 2020,39(8):2238-2245. doi: 10.1002/nau.24477. doi: 10.1002/nau.24477
[13]	Mao M, Ai F, Zhang Y, et al. Changes in the symptoms and quality of life of women with symptomatic pelvic organ prolapse fitted with a ring with support pessary[J]. Maturitas, 2018,117:51-56. doi: 10.1016/j.maturitas.2018.09.003. doi: 10.1016/j.maturitas.2018.09.003
[14]	Dwyer L, Stewart E, Rajai A. A service evaluation to determine where and who delivers pessary care in the UK[J]. Int Urogynecol J, 2021,32(4):1001-1006. doi: 10.1007/s00192-020-04532-w. doi: 10.1007/s00192-020-04532-w
[15]	Pott-Grinstein E, Newcomer JR. Gynecologists′ patterns of prescribing pessaries[J]. J Reprod Med, 2001,46(3):205-208. pmid: 11304859
[16]	Tam MS, Lee V, Yu E, et al. The effect of time interval of vaginal ring pessary replacement for pelvic organ prolapse on complications and patient satisfaction: A randomised controlled trial[J]. Maturitas, 2019,128:29-35. doi: 10.1016/j.maturitas.2019.07.002. doi: 10.1016/j.maturitas.2019.07.002
[17]	Abdulaziz M, Stothers L, Lazare D, et al. An integrative review and severity classification of complications related to pessary use in the treatment of female pelvic organ prolapse[J]. Can Urol Assoc J, 2015,9(5/6):E400-E406. doi: 10.5489/cuaj.2783. doi: 10.5489/cuaj.2783
[18]	Coelho S, Marangoni-Junior M, Brito L, et al. Quality of life and vaginal symptoms of postmenopausal women using pessary for pelvic organ prolapse: a prospective study[J]. Rev Assoc Med Bras(1992), 2018,64(12):1103-1107. doi: 10.1590/1806-9282.64.12.1103. doi: 10.1590/1806-9282.64.12.1103
[19]	Dueñas JL, Miceli A. Effectiveness of a continuous-use ring-shaped vaginal pessary without support for advanced pelvic organ prolapse in postmenopausal women[J]. Int Urogynecol J, 2018,29(11):1629-1636. doi: 10.1007/s00192-018-3586-6. doi: 10.1007/s00192-018-3586-6 pmid: 29478114
[20]	Miceli A, Fernández-Sánchez M, Polo-Padillo J, et al. Is it safe and effective to maintain the vaginal pessary without removing it for 2 consecutive years?[J]. Int Urogynecol J, 2020,31(12):2521-2528. doi: 10.1007/s00192-020-04240-5. doi: 10.1007/s00192-020-04240-5
[21]	Yoshimura K, Morotomi N, Fukuda K, et al. Changes of intravaginal microbiota and inflammation after self-replacement ring pessary therapy compared to continuous ring pessary usage for pelvic organ prolapse[J]. J Obstet Gynaecol Res, 2020,46(6):931-938. doi: 10.1111/jog.14242. doi: 10.1111/jog.14242
[22]	Arias BE, Ridgeway B, Barber MD. Complications of neglected vaginal pessaries: case presentation and literature review[J]. Int Urogynecol J Pelvic Floor Dysfunct, 2008,19(8):1173-1178. doi: 10.1007/s00192-008-0574-2. doi: 10.1007/s00192-008-0574-2
[23]	Cichowski S, Rogers RG. Nonsurgical management of a rectovaginal fistula caused by a Gellhorn pessary[J]. Obstet Gynecol, 2013,122(2 Pt 2):446-449. doi: 10.1097/AOG.0b013e31828aec98. doi: 10.1097/AOG.0b013e31828aec98 pmid: 23884255
[24]	Rapp DE, Congleton JY, Boatman K, et al. Bilateral Ureterovaginal Fistulas and Vesicovaginal Fistula in Setting of Retained Pessary[J]. Urology, 2020,141:e11-e13. doi: 10.1016/j.urology.2020.04.049. doi: 10.1016/j.urology.2020.04.049
[25]	Penrose KJ, Ma Yin J, Tsokos N. Delayed vesicovaginal fistula after ring pessary usage[J]. Int Urogynecol J, 2014,25(2):291-293. doi: 10.1007/s00192-013-2143-6. doi: 10.1007/s00192-013-2143-6
[26]	Adams TS, Cuello MA. Cancer of the vagina[J]. Int J Gynaecol Obstet, 2018,143(Suppl 2):14-21. doi: 10.1002/ijgo.12610. doi: 10.1002/ijgo.12610
[27]	Schraub S, Sun XS, Maingon P, et al. Cervical and vaginal cancer associated with pessary use[J]. Cancer, 1992,69(10):2505-2509. doi: 10.1002/1097-0142(19920515)69:10<2505::aid-cncr2820691020>3.0.co;2-o. doi: 10.1002/1097-0142(19920515)69:10&lt pmid: 1568172
[28]	Akino N, Wada-Hiraike O, Matsumoto Y, et al. Vaginal cancer possibly caused by pessary and immunocompromised condition: Multiple risk factors may influence vaginal cancer development[J]. J Obstet Gynaecol Res, 2016,42(6):748-751. doi: 10.1111/jog.12958. doi: 10.1111/jog.12958
[29]	Wilhelm P, Rolinger J, Falch C, et al. Therapy of pessary-induced rectovaginal fistula and pelvic organ prolapse in elderly patients by vaginal approach and modified LeFort colpocleisis: a case series[J]. Arch Gynecol Obstet, 2020,302(2):283-287. doi: 10.1007/s00404-020-05602-6. doi: 10.1007/s00404-020-05602-6 pmid: 32449060
[30]	Dessie SG, Armstrong K, Modest AM, et al. Effect of vaginal estrogen on pessary use[J]. Int Urogynecol J, 2016,27(9):1423-1429. doi: 10.1007/s00192-016-3000-1. doi: 10.1007/s00192-016-3000-1 pmid: 26992727
[31]	Tontivuthikul P, Sanmee U, Wongtra-Ngan S, et al. Effect of Local Estrogen Cream on Vaginal Health after Pessary Use for Prolapsed Pelvic Organ: A Randomized Controlled Trial[J]. J Med Assoc Thai, 2016,99(7):757-763. pmid: 29901374
[32]	de Albuquerque Coelho SC, Giraldo PC, Brito LGO, et al. ESTROgen use for complications in women treating pelvic organ prolapse with vaginal PESSaries (ESTRO-PESS)-a randomized clinical trial[J]. Int Urogynecol J, 2021 Jan 26. doi: 10.1007/s00192-020-04654-1. doi: 10.1007/s00192-020-04654-1
[33]	Barsky M, Kelley R, Bhora FY, et al. Customized Pessary Fabrication Using Three-Dimensional Printing Technology[J]. Obstet Gynecol, 2018,131(3):493-497. doi: 10.1097/AOG.0000000000002461. doi: 10.1097/AOG.0000000000002461